NKTR — Nektar Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $118.36m
- -$100.27m
- $98.43m
- 46
- 15
- 20
- 16
Annual cashflow statement for Nektar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -444 | -524 | -368 | -276 | -119 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 100 | 120 | 48 | 95.6 | -54.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.7 | -23.1 | 0.492 | -19.8 | -6.24 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -313 | -413 | -304 | -193 | -176 |
| Capital Expenditures | -7.26 | -15 | -5.68 | -0.865 | -1.47 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 503 | 218 | 372 | 140 | 144 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 496 | 203 | 366 | 140 | 143 |
| Financing Cash Flow Items | 146 | 3 | 0.75 | 0 | 15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -80.4 | 36.2 | 1.51 | 0.03 | 42.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 103 | -174 | 63 | -53 | 8.97 |